Sangamo Therapeutics (NASDAQ:SGMO) Trading 5.5% Higher

Shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) traded up 5.5% on Friday . The stock traded as high as $10.05 and last traded at $9.85, 1,237,045 shares were traded during trading. A decline of 32% from the average session volume of 1,811,887 shares. The stock had previously closed at $9.34.

Several research analysts have weighed in on the stock. ValuEngine raised shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 17th. HC Wainwright assumed coverage on shares of Sangamo Therapeutics in a research report on Monday, August 26th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, BidaskClub upgraded shares of Sangamo Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $12.67.

The stock’s 50-day moving average price is $9.03 and its 200-day moving average price is $10.37. The company has a market capitalization of $1.09 billion, a P/E ratio of -14.07 and a beta of 2.79.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.10. The business had revenue of $21.96 million for the quarter, compared to the consensus estimate of $12.16 million. Sangamo Therapeutics had a negative net margin of 136.73% and a negative return on equity of 27.32%. The firm’s quarterly revenue was down 6.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.13) earnings per share. As a group, research analysts forecast that Sangamo Therapeutics Inc will post -1.32 earnings per share for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Institutional investors have recently added to or reduced their stakes in the company. First Manhattan Co. purchased a new position in shares of Sangamo Therapeutics in the second quarter worth approximately $32,000. Steward Partners Investment Advisory LLC purchased a new position in Sangamo Therapeutics during the second quarter valued at approximately $50,000. Tiverton Asset Management LLC purchased a new position in Sangamo Therapeutics during the second quarter valued at approximately $79,000. Tower Research Capital LLC TRC grew its position in Sangamo Therapeutics by 1,621.1% during the third quarter. Tower Research Capital LLC TRC now owns 11,170 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 10,521 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC purchased a new position in Sangamo Therapeutics during the second quarter valued at approximately $126,000. 69.23% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

See Also: Trade Deficit

Leave a Reply

Your email address will not be published. Required fields are marked *

*